IPO round-up: ReWalk walks away with less than expected; Mevion targets $69m
This article was originally published in Clinica
Executive Summary
ReWalk Robotics has priced its initial public offering and started trading on the Nasdaq – but the total $36m raised fell short of its previous target. The firm initially said it wanted to pull in $57.5m; then reduced this target to around $51m. However, it is not all bad news: the company’s shares, which trade under the ticker symbol RWLK, were up 113% at $25.60 on 12 September, its first day of trading.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.